Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1290209
28 February 2022 02:56PM

MediClin AG: Disclosure of the preliminary figures for the 2021 financial year - result above expectations thanks to better capacity utilization in the 4th quarter of 2021


DGAP-News: MediClin AG / Key word(s): Preliminary Results
MediClin AG: Disclosure of the preliminary figures for the 2021 financial year - result above expectations thanks to better capacity utilization in the 4th quarter of 2021

28.02.2022 / 14:56
The issuer is solely responsible for the content of this announcement.


Disclosure of the preliminary figures for the 2021 financial year - result above expectations thanks to better capacity utilization in the 4th quarter of 2021


In the 2021 financial year, MEDICLIN achieved Group sales of EUR 673.1 mill. (previous year: EUR 659.9 mill.) and a consolidated operating result of EUR 11.6 mill. (previous year: EUR 0.2 mill.).

Group

The positive development in Group sales - plus EUR 13.3 mill. or 2.0% - is particularly evident if you look at the development without the protective shield benefits and a divestment in 2020. In the 2020 financial year, Group sales included protective shielding benefits of EUR 37.6 mill. as well as EUR 14.4 mill. in sales from a clinic sold on December 31, 2020. In the 2021 financial year, the protective shield benefits amounted to EUR 21.0 mill. due to the better business development. Thus, Group's sales increased based on operations by EUR 44.2 mill. or 7.3% compared to the same period of the previous year.

As far as the Group operating result is concerned, at EUR 11.6 mill. it is EUR 11.4 mill. higher than the comparative value. The reason for this pleasing development was the fact that capacity utilization in the fourth quarter of 2021 was well above expectations. The result was burdened by EUR 9.5 mill. from higher raw materials and consumables used. Staff costs rose moderately by EUR 1.2 mill. The total consolidated result is EUR 1.5 mill. (previous year: EUR -9.0 mill.).

Segments

In the post-acute segment, sales of EUR 410.8 mill. were EUR 17.1 mill. or 4.3% above the previous year's value. The sales include benefits from the protective shield in the amount of EUR 12.9 mill. (previous year: EUR 22.4 mill.). The segment thus shows operational sales growth of EUR 26.6 mill. or 7.2%. Sales in the acute segment of EUR 243.4 mill. fell by EUR 5.3 mill. or 2.1% compared to the previous year. This includes protective shielding benefits in the amount of EUR 6.8 mill. (previous year: EUR 15.0 million). As a result, operating sales (excluding protective shielding benefits and divestments) in the segment increased by EUR 15.0 mill. or 6.8%. Sales in the business area nursing care, which is part of the other activities segment, rose to EUR 17.3 mill. in the year under review (previous year: EUR 15.8 mill.). A result of EUR 15.3 mill. was achieved in the post-acute segment (previous year: EUR 4.8 mill.). In the acute segment, the result was EUR -4.0 mill. (previous year: EUR -1.5 mill.). The significantly higher cost of raw materials and consumables used had a negative effect in both segments.

Investments and staff

In 2021, gross investments in fixed assets amounted to EUR 18.1 mill. (previous year: EUR 26.6 mill.). The average number of staff, calculated as full-time employees, was 7,115 in the 2021 reporting year (previous year: 7,471 full-time employees).

The Annual Report 2021 will be available in German and English from March 30, 2022 at www.mediclin.de.

/

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 35 clinics, seven care facilities and ten medical care centers. The Group has around 8,350 beds / care places and employs around 10,200 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group.



28.02.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1290209

 
End of News DGAP News Service

1290209  28.02.2022 

fncls.ssp?fn=show_t_gif&application_id=1290209&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.